Literature DB >> 20411369

Stereotypic progressions in psychotic behavior.

Richard M Kostrzewa1, John P Kostrzewa, Rose Anna Kostrzewa, Florence P Kostrzewa, Ryszard Brus, Przemyslaw Nowak.   

Abstract

Dopamine receptor supersensitivity (DARSS) often is invoked as a mechanism possibly underlying disordered thought processes and agitation states in psychiatric disorders. This review is focused on identified means for producing DARSS and associating the role of other monoaminergic systems in modulating DARSS. Dopamine (DA) receptors, experimentally, are prone to become supersensitive and to thus elicit abnormal behaviors when coupled with DA or a receptor agonist. In intact (control) rats repeated DA D₁ agonist treatments fail to sensitize D₁ receptors, while repeated D₂ agonist treatments sensitize D₂ receptors. D₂ RSS is attenuated by a lesion with DSP-4 (N-(2-chlorethyl)-N-ethyl-2-bromobenzylamine) in early postnatal ontogeny, indicating that noradrenergic nerves have a permissive effect on D₂ DARSS. However, if DSP-4 is co-administered with 5,7-dihydroxytryptamine to destroy serotonin (5-HT) nerves, then D₂ RSS is restored. In rats treated early in postnatal ontogeny with the neurotoxin 6-hydroxydopamine to largely destroy DA innervation of striatum, both repeated D₁ and D₂ agonists sensitize D₁ receptors. 5-HT nerves appear to have a permissive effect on D₁ DARSS, as a 5-HT lesion reduces the otherwise enhanced effect of a D₁ agonist. The series of findings demonstrate that DARSS is able to be produced by repeated agonist treatments, albeit under different circumstances. The involvement of other neuronal phenotypes as modulators of DARSS provides the potential for targeting a variety of sites in the aim to prevent or attenuate DARSS. This therapeutic potential broadens the realm of approaches toward treating psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20411369     DOI: 10.1007/s12640-010-9192-0

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  46 in total

1.  Is dopamine-agonist induced yawning behavior a D3 mediated event?

Authors:  R M Kostrzewa; R Brus
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

2.  Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats.

Authors:  L Gong; R M Kostrzewa
Journal:  Pharmacol Biochem Behav       Date:  1992-03       Impact factor: 3.533

3.  Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA.

Authors:  R M Kostrzewa; L Gong
Journal:  Pharmacol Biochem Behav       Date:  1991-07       Impact factor: 3.533

4.  Induction of oral dyskinesias in naive rats by D1 stimulation.

Authors:  H Rosengarten; J W Schweitzer; A J Friedhoff
Journal:  Life Sci       Date:  1983-12-19       Impact factor: 5.037

5.  Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system.

Authors:  L Gong; R M Kostrzewa; R W Fuller; K W Perry
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

6.  Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats.

Authors:  L Gong; R M Kostrzewa; R Brus; R W Fuller; K W Perry
Journal:  Brain Res Dev Brain Res       Date:  1993-11-19

7.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

8.  Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.

Authors:  G R Breese; A Baumeister; T C Napier; G D Frye; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1985-11       Impact factor: 4.030

9.  Ontogenetic quinpirole treatment induces vertical jumping activity in rats.

Authors:  R M Kostrzewa; J Guo; F P Kostrzewa
Journal:  Eur J Pharmacol       Date:  1993-08-03       Impact factor: 4.432

10.  Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements.

Authors:  H Rosengarten; J W Schweitzer; M Egawa; A J Friedhoff
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

View more
  1 in total

Review 1.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.